Skip to main content
Top
Published in: Infectious Agents and Cancer 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

HPV18 L1 and long control region sequences variation and E6/E7 differential expression in nasopharyngeal and cervical cancers: a comparative study

Authors: Sheila Santa, Charles A. Brown, Patrick K. Akakpo, Lawrence Edusei, Osbourne Quaye, Emmanuel A. Tagoe

Published in: Infectious Agents and Cancer | Issue 1/2023

Login to get access

Abstract

Background

The role of high-risk human papillomaviruses (hr-HPVs) in cervical cancer (CC) pathogenesis has long been established. Knowledge about the involvement of hr-HPVs in the etiology of nasopharyngeal cancers (NPC) was not well appreciated until the early 2000s when a clear link began to emerge. However, it is not clear whether HPV oncogenesis in the different epithelial cancers is associated with L1 gene and long-control region (LCR) sequences variation. This study aimed to investigate the HPV18 L1 gene and LCR sequences variation in cervical and nasopharyngeal biopsies, and assessed E6 and E7 genes expression level in both cancers.

Method

Four-hundred and three (403) formalin-fixed paraffin-embedded tissues originating from nasopharyngeal (NPC) (279) and cervical (CC) (124) sites were collected from a pathology laboratory, Pathologist Without Borders, Accra, Ghana. Haematoxylin and eosin staining was carried out to confirm the presence of cancer on prepared biopsy sections. DNA was extracted from the confirmed cancer biopsies, followed by PCR using MY09/GP5+ /6+ primers to detect the presence of HPV and specific primers for the amplification of L1 gene and LCR. Sanger sequencing was carried out to determine HPV genotypes, and L1 and LCR sequences variant of HPV18s in CC and NPC biopsies. The HPV18 E6/E7 mRNA expression pattern in both cancers was determined using RT-qPCR.

Results

Most of the NPC (45%) and CC (55%) biopsies were HPV18 positive. Comparison of HPV18 L1 sequences obtained from cervical and nasopharyngeal cancer tissues, the L1 sequences from the NPC were highly dissimilar with a 59–100% variation among themselves, and in relation to the reference strains. However, the L1 sequences from the CC were more similar with a 91.0–100% variation among the amplified sequences. Also, the LCR sequences from CC were quite different relative to that of NPC. Results for the differential expression of E6/E7 in the two cancers showed a higher fold change in E6 expression in the CC tissues than the NPC tissues while a reverse expression pattern was found for E7 gene.

Conclusion

The current study reports for the first-time variations in HPV18 L1 and LCR sequences, and differential expression of E6/E7 genes in NPC compared to CC, suggesting a possible adaptation mechanism of the virus at different cancer sites.
Appendix
Available only for authorised users
Literature
1.
go back to reference de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90.CrossRefPubMed de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90.CrossRefPubMed
2.
go back to reference Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2022;11:e197–206.CrossRefPubMedPubMedCentral Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2022;11:e197–206.CrossRefPubMedPubMedCentral
3.
go back to reference Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–9.CrossRefPubMed Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–9.CrossRefPubMed
4.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed
5.
go back to reference Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2021;30(6):1035–47.CrossRef Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2021;30(6):1035–47.CrossRef
6.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–9.CrossRef Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–9.CrossRef
7.
go back to reference Shimizu Y, Murakami N, Mori T, Takahashi K, Kubo Y, Yoshimoto S, et al. Clinical impact of p16 positivity in nasopharyngeal carcinoma. Laryngosc Investig Otolaryngol. 2022;7(4):994–1001.CrossRef Shimizu Y, Murakami N, Mori T, Takahashi K, Kubo Y, Yoshimoto S, et al. Clinical impact of p16 positivity in nasopharyngeal carcinoma. Laryngosc Investig Otolaryngol. 2022;7(4):994–1001.CrossRef
8.
go back to reference Sinha S, Gajra A. Nasopharyngeal Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Sinha S, Gajra A. Nasopharyngeal Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
9.
go back to reference Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.CrossRefPubMedPubMedCentral Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Wilson R, Fehrmann F, Laimins LA. Role of the E1∧E4 protein in the differentiation-dependent life cycle of human papillomavirus Type 31. J Virol. 2005;79(11):6732–40.CrossRefPubMedPubMedCentral Wilson R, Fehrmann F, Laimins LA. Role of the E1∧E4 protein in the differentiation-dependent life cycle of human papillomavirus Type 31. J Virol. 2005;79(11):6732–40.CrossRefPubMedPubMedCentral
12.
go back to reference Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158–68.CrossRefPubMed Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158–68.CrossRefPubMed
13.
go back to reference Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 2022;174:103675.CrossRefPubMed Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 2022;174:103675.CrossRefPubMed
14.
go back to reference Burley M, Roberts S, Parish JL. Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol. 2020;42(2):159–71.CrossRefPubMedPubMedCentral Burley M, Roberts S, Parish JL. Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol. 2020;42(2):159–71.CrossRefPubMedPubMedCentral
16.
17.
go back to reference Dube Mandishora RS, Gjøtterud KS, Lagström S, Stray-Pedersen B, Duri K, Chin’ombe N, et al. Intra-host sequence variability in human papillomavirus. Papillomavirus Res. 2018;5:180–91.CrossRefPubMedPubMedCentral Dube Mandishora RS, Gjøtterud KS, Lagström S, Stray-Pedersen B, Duri K, Chin’ombe N, et al. Intra-host sequence variability in human papillomavirus. Papillomavirus Res. 2018;5:180–91.CrossRefPubMedPubMedCentral
18.
go back to reference Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2020;8:552028.CrossRefPubMed Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2020;8:552028.CrossRefPubMed
19.
20.
go back to reference Huang SH, Jacinto JCK, O’Sullivan B, Su J, Kim J, Ringash J, et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer. 2022;128(15):2908–21.CrossRefPubMed Huang SH, Jacinto JCK, O’Sullivan B, Su J, Kim J, Ringash J, et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer. 2022;128(15):2908–21.CrossRefPubMed
21.
go back to reference Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014;88(3):580–8.CrossRefPubMedPubMedCentral Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014;88(3):580–8.CrossRefPubMedPubMedCentral
22.
go back to reference Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Neck Surg. 2013;139(12):1320–7.CrossRef Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Neck Surg. 2013;139(12):1320–7.CrossRef
24.
go back to reference Saini R, Santhanam J, Othman NH, Saini D, Tang TH. Single-tube seminested PCR assay for detecting human papillomavirus in clinical samples. Open Microbiol J. 2009;3:106–12.CrossRefPubMedPubMedCentral Saini R, Santhanam J, Othman NH, Saini D, Tang TH. Single-tube seminested PCR assay for detecting human papillomavirus in clinical samples. Open Microbiol J. 2009;3:106–12.CrossRefPubMedPubMedCentral
25.
go back to reference Awua AK, Adanu RMK, Wiredu EK, Afari EA, Zubuch VA, Asmah RH, et al. Unique LCR variations among lineages of HPV16, 18 and 45 isolates from women with normal cervical cytology in Ghana. Virol J. 2017;14:85.CrossRefPubMedPubMedCentral Awua AK, Adanu RMK, Wiredu EK, Afari EA, Zubuch VA, Asmah RH, et al. Unique LCR variations among lineages of HPV16, 18 and 45 isolates from women with normal cervical cytology in Ghana. Virol J. 2017;14:85.CrossRefPubMedPubMedCentral
26.
go back to reference Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 20. Bioinforma Oxf Engl. 2007;23(21):2947–8.CrossRef Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 20. Bioinforma Oxf Engl. 2007;23(21):2947–8.CrossRef
27.
go back to reference Hall TA. Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symp Ser. 1999 Hall TA. Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symp Ser. 1999
28.
go back to reference Derbie A, Maier M, Amare B, Misgan E, Nibret E, Liebert UG, et al. High-risk human papillomavirus genotype distribution among women with gynecology complaints in northwest Ethiopia. Infect Agent Cancer. 2023;18(1):4.CrossRefPubMedPubMedCentral Derbie A, Maier M, Amare B, Misgan E, Nibret E, Liebert UG, et al. High-risk human papillomavirus genotype distribution among women with gynecology complaints in northwest Ethiopia. Infect Agent Cancer. 2023;18(1):4.CrossRefPubMedPubMedCentral
29.
go back to reference Donkoh ET, Asmah RH, Agyemang-Yeboah F, Dabo EO, Wiredu EK. Prevalence and distribution of vaccine-preventable genital human papillomavirus (HPV) genotypes in Ghanaian women presenting for screening. Cancer Control. 2022;29:10732748221094720.CrossRefPubMedPubMedCentral Donkoh ET, Asmah RH, Agyemang-Yeboah F, Dabo EO, Wiredu EK. Prevalence and distribution of vaccine-preventable genital human papillomavirus (HPV) genotypes in Ghanaian women presenting for screening. Cancer Control. 2022;29:10732748221094720.CrossRefPubMedPubMedCentral
30.
go back to reference Khasawneh AI, Himsawi N, Abu-Raideh J, Salameh M, Abdullah N, Khasawneh R, et al. Prevalence of human papillomavirus associated with head and neck squamous cell carcinoma in Jordanian patients. Open Microbiol J. 2020;14(1). Khasawneh AI, Himsawi N, Abu-Raideh J, Salameh M, Abdullah N, Khasawneh R, et al. Prevalence of human papillomavirus associated with head and neck squamous cell carcinoma in Jordanian patients. Open Microbiol J. 2020;14(1).
31.
go back to reference Nartey Y, Amo-Antwi K, Hill PC, Dassah ET, Asmah RH, Nyarko KM, et al. Human papillomavirus genotype distribution among women with and without cervical cancer: implication for vaccination and screening in Ghana. PLoS ONE. 2023;18(1):e0280437.CrossRefPubMedPubMedCentral Nartey Y, Amo-Antwi K, Hill PC, Dassah ET, Asmah RH, Nyarko KM, et al. Human papillomavirus genotype distribution among women with and without cervical cancer: implication for vaccination and screening in Ghana. PLoS ONE. 2023;18(1):e0280437.CrossRefPubMedPubMedCentral
32.
go back to reference Okerosi S, Mokoh LW, Rubagumya F, Niyibizi BA, Nkya A, Van Loon K, et al. Human papillomavirus-associated head and neck malignancies in sub-Saharan Africa: a systematic review. JCO Glob Oncol. 2023;9:e2200259.CrossRefPubMedPubMedCentral Okerosi S, Mokoh LW, Rubagumya F, Niyibizi BA, Nkya A, Van Loon K, et al. Human papillomavirus-associated head and neck malignancies in sub-Saharan Africa: a systematic review. JCO Glob Oncol. 2023;9:e2200259.CrossRefPubMedPubMedCentral
33.
go back to reference Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM, IARC HPV Variant Study Group. Human papillomavirus 18 genetic variation and cervical cancer risk worldwide. J Virol. 2015;89:10680–7.CrossRefPubMedPubMedCentral Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM, IARC HPV Variant Study Group. Human papillomavirus 18 genetic variation and cervical cancer risk worldwide. J Virol. 2015;89:10680–7.CrossRefPubMedPubMedCentral
35.
go back to reference Syrjänen S, Rautava J, Syrjänen K. HPV in Head and Neck Cancer—30 Years of History. In: Golusiński W, Leemans CR, Dietz A, editors. HPV Infection in Head and Neck Cancer. Cham: Springer International Publishing; 2017. pp. 3–25 (Recent Results in Cancer Research; vol. 206). https://doi.org/10.1007/978-3-319-43580-0_1 Syrjänen S, Rautava J, Syrjänen K. HPV in Head and Neck Cancer—30 Years of History. In: Golusiński W, Leemans CR, Dietz A, editors. HPV Infection in Head and Neck Cancer. Cham: Springer International Publishing; 2017. pp. 3–25 (Recent Results in Cancer Research; vol. 206). https://​doi.​org/​10.​1007/​978-3-319-43580-0_​1
36.
go back to reference Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33.CrossRefPubMed Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33.CrossRefPubMed
37.
go back to reference Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R. Five-year relative survival for human papillomavirus-associated cancer sites. Cancer Cytopathol. 2018;124(1):203–11.CrossRef Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R. Five-year relative survival for human papillomavirus-associated cancer sites. Cancer Cytopathol. 2018;124(1):203–11.CrossRef
38.
go back to reference Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta BBA Rev Cancer. 2021;1876(1):188556.CrossRef Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta BBA Rev Cancer. 2021;1876(1):188556.CrossRef
Metadata
Title
HPV18 L1 and long control region sequences variation and E6/E7 differential expression in nasopharyngeal and cervical cancers: a comparative study
Authors
Sheila Santa
Charles A. Brown
Patrick K. Akakpo
Lawrence Edusei
Osbourne Quaye
Emmanuel A. Tagoe
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2023
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-023-00560-5

Other articles of this Issue 1/2023

Infectious Agents and Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine